Vertex Pharmaceuticals Inc (VRTX)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$499.64

Buy

$499.90

arrow-up$0.91 (+0.18%)

Prices updated at 02 May 2025, 19:47 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
NASDAQ
arrow-up1.76%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Jeffrey M Leiden, PhD
CEO
Dr. Reshma Kewalramani, M.D.
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
6,100
Head office
50 Northern Avenue
Boston
United States
02210
mobile
+1 617 341-6100
letter
investorinfo@vrtx.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. Charles F. Wagner, Jr
Executive Vice President and Chief Financial Officer
0.88m
Mr. Stuart A. Arbuckle
Executive Vice President and Chief Operating Officer
0.94m
Mr. Duncan J. McKechnie
Senior Vice President and Head, North America Commercial Team
-
Mr. Amit K. Sachdev, J.D.
Executive Vice President and Chief Patient and External Affairs Officer
-
Mr. Bruce I. Sachs
Lead Independent Director
0.18m
Mr. Lloyd A. Carney
Independent Director
0.14m
Dr. Jeffrey M Leiden, PhD
Executive Chairman of the Board
-
Dr. Alan M. Garber, M.D.,PhD
Independent Director
0.12m
Mr. Suketu Upadhyay
Independent Director
0.14m
Mr. Michel Lagarde
Independent Director
0.11m
Dr. David Altshuler, M.D.,PhD
Executive Vice President and Chief Scientific Officer
0.88m
Dr. Sangeeta N. Bhatia, PhD
Independent Director
0.14m
Ms. Diana L. McKenzie
Independent Director
0.13m
Dr. Reshma Kewalramani, M.D.
Director, President and Chief Executive Officer
1.54m
Mr. Jonathan Biller
Executive Vice President and Chief Legal Officer
-
Dr. Jennifer Schneider, M.D.
Independent Director
0.07m
Dr. Ourania Tatsis, PhD
Executive Vice President and Chief Regulatory and Quality Officer
-
Dr. Carmen Bozic
Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
-
Ms. Nancy A. Thornberry
Independent Director
0.11m
Ms. Kristen C. Ambrose
Senior Vice President and Chief Accounting Officer
-
Dr. E Morrow Atkinson, III, PhD
Executive Vice President, Chief Technical Operations Officer and Head, Biopharmaceutical Science and Manufacturing Operations
-
Dr. Nia Tatsis
Executive Vice President and Chief Regulatory and Quality Officer
0.69m

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Capital Research and Management Company42,414,577
Capital Group29,255,419
Capital World Investors28,325,695
Vanguard Group Inc23,258,288
BlackRock Inc21,825,470

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
15 Nov 2024-
11 Nov 2024-
08 Nov 2024-
15 Oct 2024-
01 Oct 2024-
02 Oct 2024-
30 Aug 2024-
30 Aug 2024-
30 Aug 2024-
30 Aug 2024-
08 Aug 2024-
08 Aug 2024-
08 Aug 2024-
07 Aug 2024-
01 Aug 2024-
01 Aug 2024-
01 Aug 2024-
30 Jul 2024-
24 Jul 2024-
22 Jul 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.